Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Hemab Therapeutics Holdings, Inc.

COAG · Nasdaq · USD · Market cap $1.9B · 59 employees

Hemab Therapeutics Holdings, Inc.

FAIL · Does not pass the screen
39.29 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price39.29 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $54.00 to $70.00, base estimate $64.00 (screen dated 2026-11-20).

Current read
Markup ?
Undervalued · screened 2026-11-20
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price39.29 USD
Fair value64.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-17Read Markup40.86-3.8% to today Accumulation gives way to Markup after a 10% slide in 11 days
2026-11-06Read Accumulation45.57-13.8% to today Markup gives way to Accumulation after a 13% rise in 7 days
2026-10-30Read Markup40.42-2.8% to today Distribution gives way to Markup after a 24% rise in 8 days
2026-10-22Read Distribution32.52+20.8% to today Markdown gives way to Distribution after a 34% slide in 6 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Hemab Therapeutics Holdings, Inc. holds its Markup at $39.29. The statistical read favours the buyers, held for 1 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateThe statistical read favours the buyers, held for 1 days
Price at the screen$39.29
ValuationN/A trailing · -15.04 forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens: COAG's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.63% Below 33% Pass
Interest-bearing cash 50.06% Below 33% Fail
Receivables 46.51% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Hemab Therapeutics Holdings,'s business is fine, but its cash and interest-bearing securities are about 50% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when COAG's ethical verdict changes

Today COAG does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 39% discount to our $64.00 fair value.

Method.

54.00Conservative64.00Base case70.00Growth case 39.29Price

USD, 2026-11-20 screen. A 38.6% under base.

The Street's Range
54.00Street low 64.00Street average 70.00Street high 39.29Price

Street: 7 covering, consensus Strong Buy. Average target +63%.

Chart
The Business, in Plain Words

Early stage biotech with almost no safety margin

A patient with a rare clotting disorder waits for a new therapy that might never reach the clinic. Hemab is still at that early point, burning cash with zero profit margin and a forward multiple that sits deep in negative territory. The shares trade right at our calculated value, leaving no real buffer if trials slip.

We pass because the ethical screen returns insufficient data and the business offers no proven moat or earnings visibility. Analyst targets cluster at the current price, which simply confirms the market already prices in modest success without rewarding extra risk.

High failure rates in coagulation drug development, repeated dilution, and the complete absence of financial ratios all point to an incomplete picture rather than a compelling opportunity. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-15.0x
EPS, trailing-3.55
EPS, forward-2.65
Profit margin0.0%currently unprofitable
Debt to equity0.23minimal debt: a conservative balance sheet
Current ratio33.86comfortably covers its short-term bills
52-week range23.00 - 55.42
Market cap$1.9B
Employees59

COAG-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $39.86 -2.4% Entry 13
2026-11-17 Markup · changed $40.86 -4.6% Entry 12

The framework has shifted from accumulation to markup since the last review.

2026-11-10 Accumulation $42.81 -12.7% Entry 11
2026-11-09 Accumulation $49.02 +0.0% Entry 10
2026-11-08 Accumulation $49.02 +0.0% Entry 9
2026-11-07 Accumulation $49.02 +7.6% Entry 8
2026-11-06 Accumulation · changed $45.57 +1.1% Entry 7

The framework has shifted from markup to accumulation since the last review.

2026-11-05 Markup $45.09 +11.6% Entry 6

Earnings landed in this window.

2026-10-30 Markup · changed $40.42 +24.3% Entry 5

The framework has shifted from distribution to markup since the last review.

2026-10-22 Distribution · changed $32.52 +2.8% Entry 4

The framework has shifted from markdown to distribution since the last review. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on COAG

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in COAG's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $25.00 -0.1% · $999 -0.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever COAG does next, these words stay.

Hemab Therapeutics Holdings, Inc. · COAG · Markup · $39.29
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.